Photodynamic therapy in conjunction with intraocular implants

• US 20050244466A1
• Filed: 04/30/2004
• Published: 11/03/2005
• Est. Priority Date: 04/30/2004
• Status: Abandoned Application

• Current Assignee: Allergan, Inc. (Canada) (Abbvie Incorporated)
• Original Assignee: Allergan, Inc. (Canada) (Abbvie Incorporated)
• Inventors: Whitcup, Scott M., Burke, James A.
• Application Number:
  US10/837,348
• Publication Number:
  US 20050244466A1
• Time in Patent Office: Days
• US Class Current: 424/427
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/409 having four such rings, e.g. porphine derivatives, bilirubin, biliverdine hemin, hematin A61K31/555
• CPC Class Codes: A61K 31/555 containing heavy metals, e.g. hemin, hematin, melarsoprol
• CPC Class Codes: A61K 31/573 substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
• CPC Class Codes: A61K 41/0057 Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
• CPC Class Codes: A61K 41/0071 PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
• CPC Class Codes: A61K 9/0051 Ocular inserts, ocular implants
• CPC Class Codes: A61K 9/1647 Polyesters, e.g. poly(lactide-co-glycolide)

Abstract

A method for treating an ocular condition is provided. The method includes the steps of placing into an eye, a bioerodible implant comprising an anti-inflammatory component and a bioerodible polymeric component in order to provide extended dosing of anti-inflammatory agent to the eye, and treating the eye with photodynamic therapy. The step of treating the eye with photodynamic therapy may include introducing a photoactive agent into the eye, and irradiating the eye with electromagnetic radiation, for example light energy, for example laser energy, in order to activate the photoactive agent in the eye and treat the ocular condition.

Claims

1. A method for treating an eye, the method comprising the steps of:

placing into an eye, a bioerodible implant comprising an anti-inflammatory component and a bioerodible polymeric component;

introducing a photoactive agent into the eye; and

irradiating the eye to activate the photoactive agent.

2. The method of claim 1 wherein the photoactive agent comprises porphyrin.

3. The method of claim 1 wherein the photoactive agent comprises verteporfin.

4. The method of claim 1 wherein the photoactive agent is selected from the group consisting of hematoporphyrins, hematoporphyrin derivatives, pheophorbides, derivatives of pheophorbides, bacteriochlorins, purpurins, merocyanines, porphycenes, and combinations thereof.

5. The method of claim 1 wherein the anti-inflammatory component comprises a steroidal anti-inflammatory agent.

6. The method of claim 1 wherein the anti-inflammatory component is selected from the group consisting of cortisone, dexamethasone, fluocinolone, hydrocortisone, methylprednisolone, prednisolone, prednisone, and triamcinolone, derivatives thereof and mixtures thereof.

7. The method of claim 1 wherein the anti-inflammatory component is selected from the group consisting of corticosteroids and mixtures thereof.

8. The method of claim 1 wherein the anti-inflammatory component is dexamethasone.

9. The method of claim 1 wherein the bioerodible implant further comprises an ophthalmically acceptable therapeutic agent in addition to the anti-inflammatory component.

10. The method of claim 1 wherein the anti-inflammatory component is associated with the bioerodible polymeric component.

11. The method of claim 1 wherein the anti-inflammatory component is dispersed within the bioerodible polymer component.

12. The method of claim 1 wherein the bioerodible polymeric component is a matrix material.

13. The method of claim 1 wherein the bioerodible polymeric component comprises a mixture of a first biodegradable polymer having terminal acid groups, and a second biodegradable polymer having terminal acid groups.

14. The method of claim 13 wherein the first biodegradable polymer is a poly(D,L-lactide-co-glycolide).

15. The method of claim 14 wherein the second biodegradable polymer is a poly(D,L-lactide).

16. The method of claim 1 wherein the bioerodible polymeric component includes a polymeric material selected from the group consisting of polymers of poly-lactic acid, polymers of poly glycolic acid, copolymers of lactic acid and glycolic acid and mixtures thereof.

17. The method of claim 1 wherein the bioerodible polymeric component includes a polymeric material selected from the group consisting of copolymers of lactic acid and glycolic acid, and mixtures thereof.

18. The method of claim 1 wherein the step of introducing a photoactive agent comprises intravenously introducing the photoactive agent.

19. The method of claim 1 wherein the step of irradiating the eye comprises subjecting the eye to laser irradiation.